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he American Diabetes Association’s
57th Annual Advanced Postgraduate
Course was held 5–7 February 2010
in San Francisco, California. Free webcasts
ofthetalksfromthe57thAnnualAdvanced
Postgraduate Course are available at http://
professional.diabetes.org/pg10.
Bariatric surgery in diabetes
Lee Kaplan (Boston, MA) discussed new
information based on studies of bariatric
surgery in diabetes. Surgery is performed
in 0.25% of Americans with obesity, so it
is unlikely that it in itself can address the
U.S.diabetesorobesityissues,butlessons
from its use may shed light on the ap-
proach to obesity and diabetes for the
overallpopulation.Thebiologyofobesity
suggests that it is caused by inactivity and
overnutriton and likely stress as well.
There is a huge burden of obesity-
associated illness, including malignancy,
and obesity has a devastating effect on
quality of life and also on what is termed
societal “efﬁcacy” and socioeconomic sta-
tus. The physiology of obesity involves
central regulation of food intake, nutrient
handling, and energy expenditure, with
adipose tissue energy stores regulating
levels of signals such as leptin, and infor-
mation from liver, muscle, and bone on
metabolic needs coupled with informa-
tion from the gastrointestinal tract and
sensoryorgansregardingthequantityand
quality of nutrient intake. A unifying
theme is the body’s defense of fat (rather
than of total body weight).
Surgery includes the Roux-en-Y com-
bination gastric restriction and bypass
(RYGB) of distal stomach, duodenum,
and proximal jejunum, which is the most
effective, and may be the most appropri-
ate, for diabetes treatment. Adjustable
gastricbandingisagastricrestrictionpro-
cedure, while vertical sleeve gastrectomy
removes the greater curvature of the
stomach,actinginafashionverydifferent
from gastric banding, causing more rapid
gastric emptying. In the Swedish Obesity
Study, lifestyle was compared with bari-
atric procedures. Gastric banding led to
20% weight loss initially, which de-
creased to 14% after a decade. RYGB led
to 38% weight loss initially, decreasing to
28% at 10 years. Lifestyle modiﬁcation
led to an initial weight loss of 7%, drop-
ping to 2% at 10 years. Gastric bypass
improved all and cured 18% of diabetes
(1). In a retrospective cohort study of
9,949 patients who had undergone gas-
tric bypass surgery and 9,628 severely
obeseindividualswhoappliedfordriver’s
licenses in Utah, a 7.1-year follow-up of
7,925 age-, sex-, and BMI-matched pairs
showed mortality reduction of 40%, with
56% less coronary disease–related mor-
tality (2). There are, of course, adverse
outcomes, and neither study was a ran-
domized controlled trial. Currently ac-
cepted indications for surgery in
individualsforwhomotherapproachesto
weight loss have failed are 1) BMI 40
kg/m
2 or 2) BMI 35 kg/m
2 with major
medical complications of obesity. A total
of 250,000 such operations are per-
formed annually in the U.S.—far fewer
than the 10 million people who ﬁll these
criteria. Contraindications include severe
cirrhosis, unstable coronary disease, psy-
chiatric illness, noncompliance, and sub-
stance abuse.
It is not clear, Kaplan pointed out,
why gastric bypass is so effective. It ap-
pears to alter both endocrine and neuro-
nal gastrointestinal signals to the brain,
pancreas, and liver rather than just exert-
ing a mechanical effect in decreasing food
intake. Dramatic effects on hunger and
satiety are seen, but few patients become
underweight and then usually only in as-
sociation with major surgical complica-
tions. Because the improvement in
metabolism often reestablishes ovulation,
it is noteworthy that there is weight gain
in women who have had the procedures
and then become pregnant. When the
procedures are carried out in thin people
or in animals, weight loss does not occur.
Changes are variously reported in endo-
crinemarkerssuchasghrelin,peptideYY,
glucagon-like peptide-1, and glucose-
dependent insulinotropic polypeptide,
and bariatric surgery causes increased en-
ergy expenditure. It may, then, increase
the effectiveness of gastrointestinal sig-
nals and, hence, physiologically create an
overfed state that leads to weight loss to
attain a new set point. In contrast to the
improvements seen after surgery, with
diet, appetite increases, energy expendi-
ture decreases, and stress responses in-
crease. RYGB reduces food intake and
changes food preference, central dopa-
minesignaling,energyexpenditure,insu-
lin sensitivity, pancreatic -cell biology,
lipid metabolism, and gastrointestinal
mucosal remodeling. Its effects on diabe-
tes are profound, with the condition re-
solving in 45% of patients after gastric
banding, 85% after sleeve gastrectomy or
gastric bypass, and 98% after the more
radical bilio-pancreatic diversion, corre-
lating with weight loss after gastric band
procedures but exceeding the degree of
weight loss with the latter three ap-
proaches, perhaps because of changes in
gastrointestinal hormone signaling inde-
pendent of weight loss.
In an animal model, RYGB induces
weightlossfromreductioninfatmassand
fasting glucose improves, as does glucose
tolerance. In a relatively lean animal
model of insulin resistance and diabetes,
comparing diet-induced and RYGB
weight loss, both reduce development of
fasting hyperglycemia, but patients un-
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erance, with an increase in islet cell mass
andimprovementinhistologyandinsulin
content.
RYGB involves gastric restriction, al-
teredgastricfunction,andexclusionfrom
the digestive pathway of the distal stom-
ach, duodenum, and proximal jejunum.
With use of a plastic sleeve to exclude the
mucosa of the duodenum and jejunum,
weight, fasting glucose, and insulin levels
decrease while insulin sensitivity in-
creases, mimicking many aspects of
RYGB; such an approach is now being ex-
plored with an endoluminal duodenal
barrier as a bariatric therapy. Gastric sur-
gery alone changes weight and food in-
take but has little effect on energy
expenditure and glucose metabolism,
while duodenal barrier and ileal interpo-
sition procedures have less effect on
weightandfoodintakeandmoreeffecton
energy expenditure and glucose metabo-
lism,withRYGBaffectingalltheseparam-
eters. Reasoning that “efﬁcacy has to be
matched against risk and cost,” Kaplan
suggested that the procedures have bene-
ﬁts outweighing risk, although he does
not recommend gastric banding because
20% of patients undergoing this proce-
dure subsequently require RYBG, which
then has markedly increased risk. It may
be possible, he suggested, to devise ap-
proaches with multiple pharmaceutical,
nutritional, and “nutriceutical” agents,
perhaps also using endoscopically placed
devices to mimic the effects of surgery.
Exercise for diabetes
Judith Regensteiner (Aurora, CO) dis-
cussed prescription of exercise for diabe-
tes, noting decreased ability to exercise
among diabetic individuals even early in
thedisease,perhapsrelatedtounderlying
cardiac abnormality, leading to a vicious
cycle of physical inactivity perpetuating
insulin resistance. The Diabetes Preven-
tion Program and Finnish Diabetes Pre-
vention Study participants who did not
lose weight but were physically active
were protected to some extent from de-
veloping diabetes. Discomfort during ex-
ercise, Regensteiner noted, is more often
perceived by diabetic than by weight-
matched nondiabetic individuals, with-
outclearexplanation,butposingabarrier
to exercise for diabetic patients. Diabetes
is associated with reduction in maximal
oxygen uptake, a clinically relevant car-
diovascular ﬁtness marker. Diabetic
women show reduced exercise tolerance,
but this may be particularly improved in
thesepatientsasopposedtointhosewith-
out diabetes, as demonstrated in a trial of
exercisetraining(3).Diabeticwomenina
supervisedaerobicandresistancetraining
intervention 3 days per week for a period
of 10 weeks had improved oxygen con-
sumption and large artery compliance in
another study (4). In a comparison of di-
abetic women with healthy control
women, the major difference was in in-
creased pulmonary capillary wedge pres-
sure during exercise, suggesting diastolic
dysfunction/heartstiffness.Nuclearstress
testing showed decreased total myocar-
dialperfusion,correlatingnegativelywith
pulmonary capillary wedge pressure, an
apparent cardiac abnormality seen early
in diabetes (5). Echocardiographic stud-
ies of type 2 diabetic and obese adoles-
cents have shown a correlation between
decreased insulin sensitivity and reduc-
tion in oxygen utilization, and Regen-
steiner speculated that insulin resistance
might be causally related to the cardiac
abnormalities (6).
Physical activity has been shown to
improve cardiovascular risk and reduce
mortality in diabetic patients in cross-
sectional studies (7). In the National
Health Interview Survey, an 8-year fol-
low-up of 2,896 adults with diabetes
showed that those who reported walking
3–4 h weekly, or those who reported suf-
ﬁciently strenuous walking to increase
their heart and breathing rates, had
50% lower mortality, regardless of sex,
age, race, BMI, diabetes duration, comor-
bid conditions, and physical limitations
(8).Ameta-analysisof14controlledtrials
ofexerciseindiabeticindividualsshowed
an A1C reduction from 8.3 to 7.7% but
no signiﬁcant weight loss, further sug-
gesting potential beneﬁt (9).
Why, Regensteiner asked, does exer-
cise help? Exercise improves endothelial
function (10), and acute episodes of exer-
cise may increase tissue blood ﬂow, with
the resulting shear stress stimulating ni-
tric oxide synthesis. Exercise may reduce
inﬂammationandappearstodecreaseab-
dominal visceral fat (11), with the conse-
quent improvement in body composition
perhaps being more important than
weight loss per se in improving insulin
sensitivity. “Exercise,” she concluded, “is
medicine—it’s free medicine!” Rather
than recommending vigorous exercise, as
previously suggested, the current physi-
cal activity guidelines suggest at least 30
min of moderate-intensity physical activ-
ity at least 5 days weekly, and in addition
to that adults should perform muscle-
strengthening exercises (12). Aerobic ex-
ercise should be performed ﬁve times
weekly at 55–85% of the maximal heart
rate, calculated as 220  age, and resis-
tance exercise twice weekly, with 12–15
repetitions at an intensity of one-third to
one-half of the one-repetition maximal,
performing 8–10 different exercises. For
children, twice as much activity is recom-
mended, as well 1 h daily of television
plus computer time. Walking is particu-
larly recommended. The average in the
U.S., in a study of 111 individuals wear-
ing pedometers, was 4,000–5,000 steps
daily, with a reasonable goal of 10,000
steps daily (13). The use of a pedometer
may be helpful in giving patients a sense
of accountability, although it is then im-
portant that the health care professional
reviewtheexerciselog.Shesuggestedthat
appropriate footwear, attention to blood
pressure control, appropriate advice for
prevention of hyper- and hypoglycemia,
and avoidance of heavy straining for indi-
viduals with retinopathy are all reason-
able. Regensteiner reviewed indications
for cardiac stress testing, suggesting that
this be done with typical or atypical car-
diac symptoms, resting electrocardio-
gram abnormality, and peripheral or
carotid arterial disease and in individuals
with a sedentary lifestyle who plan to be-
gin vigorous exercise. She pointed out
thatexercisetestsareoftenabnormalwith
diabetic cardiomyopathy, cardiovascular
autonomic neuropathy, and renal insufﬁ-
ciency, with such individuals requiring
echocardiographic or nuclear stress
testing.
Glycemic control in hospital
Mary Korytkowski (Pittsburgh, PA) dis-
cussed glycemia control in hospitalized
patients, addressing the glycemic targets
and appropriate approaches. “The study
that really reawakened the medical com-
munity” by Van Den Berghe in 2001 laid
to rest the notion that the most important
aspect of diabetes treatment was simply
the avoidance of hypoglycemia, showing
that intensive glycemic management re-
duced requirement for ventilatory sup-
port, transfusion, dialysis, and sepsis
treatment and, most impressively, re-
duced intensive care unit mortality (14).
Glucose levels in the intensively treated
group were maintained between 80 and
110mg/dl,whereasthecontrolgrouplev-
els were 200 mg/dl, leading many to
express concern about risk of hypoglyce-
mia.Reanalysisofthestudy,however,did
suggest particular beneﬁt in the group
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from this group have shown a beneﬁcial
effectofintensivetreatmentininfantsand
children, with reduction both in infec-
tionsandinmortality.Inthisstudy,how-
ever, hypoglycemia occured in 4.9% of
intensively treated patients, but in 0.9%
of control subjects, showing the need for
careful monitoring (16). Subsequent
studies have not clearly shown beneﬁt,
with evidence of adverse effect, but inter-
pretation of the studies is complicated by
six- to eightfold higher rates of hypogly-
cemiaandbylesserdifferenceinglycemia
between the intervention and control
groups (17–19). In the large, interna-
tional, randomized trial Normoglycaemia
in Intensive Care Evaluation Survival Us-
ingGlucoseAlgorithmRegulation(NICE-
SUGAR) comparing mean glucose levels
of 118 vs. 145 mg/dl during the typical
4–5 day period of insulin infusion, hypo-
glycemia, deﬁned by glucose 40 mg/dl,
occurred in 6.5 vs. 0.5% of patients, re-
spectively,and90-daymortalitywas14%
greater with intensive glycemic treatment
at 27.5 vs. 24.9%, leading to the conclu-
sion, “the guidelines needed to change”
(20). Korytkowski noted the far later
occurrence of mortality than of hypogly-
cemia, leading to the “open question”:
whatwasthemediatoroftheadverseout-
come? A meta-analysis that included
NICE-SUGARshowednosigniﬁcantben-
eﬁt of intensive insulin treatment (21).
Korytkowski asked the audience, how-
ever, to “remember that conventional
therapy was not really poor control” but,
rather, a mean level of 140–150 mg/dl.
Explanations abound, including variabil-
ity in insulin-management protocols, the
difference between multicenter and indi-
vidual center studies, arterial versus ve-
nousversuscapillaryglucosemonitoring,
laboratory testing versus point-of-care
glucose meters, and variability in the du-
ration of hyperglycemia prior to random-
ization. The original Leuven study
comprised a postoperative group, so the
onset of hyperglycemia could be com-
pletely eliminated. Sepsis was prevented
in the Leuven study, while patients al-
ready having severe sepsis, Korytkowski
said, “may in fact be too ill for intensive
insulin therapy.” A study of 12 healthy
males injected with lipopolysaccharide to
produce endotoxemia showed an in-
creaseininsulinsensitivityattheliverand
periphery (22); individuals with sepsis
would require particular caution in insu-
lin administration. Point-of-care glucose
meters have shown variability of up to
32% from laboratory glucose measures,
whichwouldofcoursebeamajorissuein
titrating intravenous insulin for intensive
glycemic control. Whole blood, polycy-
themia, oxygen, and acetaminophen de-
crease glucose readings with various
methodologies, whereas anemia and
other factors may increase glucose
readings.
There is no doubt that hypoglycemia
increases levels of cortisol and epineph-
rine, and also of cytokines such as inter-
leukin-1, interleukin-8, and tumor
necrosis factor- (23), and so “could
undothebeneﬁts.”Hypoglycemiaisasso-
ciated with increased hospital length of
stay (24). Is there, then, any reason to
pursue glycemic control in critically ill
patients? Comparing poor with excellent
glycemic control, there is a marked in-
crease in post-sternotomy wound infec-
tion (25) and in total infection rates (26)
and a progressive increase in mortality
(27). It may be that an appropriate glyce-
mic target is that of the conventional
treatmentgroupinNICE-SUGAR:insulin
wasstartedforglucose180mg/dl,anda
mean glucose level of 144 mg/dl was
achieved. Intravenous insulin, Koryt-
kowski stated, should start at 140–180
mg/dl, using a proven safety/efﬁcacy pro-
tocol with acceptable ease of use and in-
cidence of hypoglycemia.
What of patients outside critical care
units? Hyperglycemia is associated with
increase in mortality, and this is particu-
larly so for those with new-onset hyper-
glycemia rather than for patients with
established diabetes (28). During exacer-
bation of chronic obstructive lung dis-
ease, a stepwise increase in adverse
outcomehasbeenseenatglucoselevelsof
108, 108–124, 125–160, and 160
mg/dl (29). We need, then, to “identify
reasonable, achievable, and safe glucose
targets.” A reasonable recommendation is
that of the American Association of Clin-
ical Endocrinologists and American Dia-
betes Association consensus statement on
inpatientglycemiccontrol,aimingforlev-
elsof140–180mg/dlingeneraland110–
140 mg/dl in cardiothoracic intensive
care unit patients, with 100–140 mg/dl
premeal and other levels 180 mg/dl.
Hospitalhyperglycemiaiscurrentlybeing
deﬁned as any glucose 140, with stress
hyperglycemia refering to elevated glu-
cose in patients without prior history of
diabetes, for which one may use A1C
6.5% in screening (with appropriate
cautions as to factors affecting A1C). Hy-
poglycemia is deﬁned as 70 mg/dl and
severe hypoglycemia 40 mg/dl. “How,”
Korytkowski asked, “do we get there
safely?” In non–critically ill patients,
insulin is preferred as scheduled basal-
bolus therapy with correctional compo-
nents rather than treatment with sliding-
scale insulin. Insulin is preferred because
sulfonylureas cause hypoglycemia, par-
ticularly with variable meals, metformin
is often contraindicated, thiazolidinedio-
nes cause edema and heart failure and re-
quire weeks to months for onset of
glycemic action, -glucosidase inhibitors
are relatively weak, and pramlintide and
glucagon-like peptide-1 agonists can
cause nausea and exert greater postpran-
dial effect. An approach is to institute
treatment with a total daily dose of 0.2–
0.4 units/kg body wt, with 50–60% as
basal insulin, using correction insulin for
glucose levels above goal and adjusting
according to results of bedside glucose
monitoring. Such regimens lead to better
mean glycemia without increase in hypo-
glycemia compared with sliding scale–
only treatment approaches (30), and the
use of insulin analogs leads to less hypo-
glycemiathandohumanandNPHinsulin
(31).
Enteral or parenteral nutrition and
glucocorticoid therapy are predictors of
risk of hyperglycemia with and without
known diabetes, so one should monitor
glucose in these patients and administer
insulin accordingly, recognizing the need
to adjust insulin proactively as nutrition
treatment or glucocortocoid doses are
modiﬁed both in the hospital and when a
patient on such treatment is discharged.
Korytkowski reviewed her study of pa-
tients starting enteral nutrition, which
shows a reduction in hypoglycemia with
insulin glargine given prospectively
rather than a human or NPH insulin reg-
imen (32). She suggested that for the spe-
cial case of patients receiving insulin
pump treatment, it is reasonable that pa-
tients continue such treatment “provided
they have the mental and physical capac-
ity to do so” but with available hospital
personnel with expertise in the use of
pumps and with a formal inpatient insu-
lin pump protocol to reduce confusion
and treatment variability (33).
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